Journal of Clinical Oncology
Articles in this Issue
Single-cycle neoadjuvant pembrolizumab in patients with stage I-III MMR-deficient colon cancer: Final analysis of the RESET-C study.
19 Background: Neoadjuvant treatment with immune checkpoint inhibitors has shown remarkable responses in patients with deficient mismatch repair (dMMR) co...
Trajectories of premorbid healthcare contact days in veterans with pancreatic cancer.
706 Background: Early detection of pancreatic cancer is a key clinical priority. Although prior work has evaluated machine learning models to identify at-...
Impact of COVID-19 on colorectal cancer screening using Medicare Centers for Medicare and Medicaid Services (CMS) claims data.
91 Background: When COVID-19 pandemic started in 2020 in the US, the Centers for Medicare and Medicaid Services (CMS) recommended that all non-urgent proc...
Safety, efficacy, and on-treatment circulating tumor DNA (ctDNA) changes from a phase 1 study of RMC-6236, a RAS(ON) multi-selective, tri-complex inhibitor, in patients with RAS mutant pancreatic ductal adenocarcinoma (PDAC).
722 Background: PDAC is the third leading cause of cancer mortality, with limited treatment options. Even with multi-agent...
Germline pathogenic variants in a cohort of individuals with biliary tract cancer.
559 Background: Biliary tract cancers (BTC) are rare but have been implicated in hereditary cancer conditions such as Lynch syndrome (LS) and...
Preliminary result of a phase Ib study: Efficacy and safety of FG-M108 plus gemcitabine/nab-paclitaxel as first-line (1L) treatment in patients with Claudin18.2-positive locally advanced unresectable or metastatic (LA/m) pancreatic cancer.
729 Background: FG-M108, an ADCC-enhanced anti-CLDN18.2 monoclonal antibody, showed significant efficacy in 1L treatment of gastric cancer. Herein, we rep...
Outcome of radiation related esophageal stricture from endoscopic dilation.
387 Background: Esophageal strictures present a significant challenge, particularly in cases of radiation-induced strictures. Esophageal dilation is a com...
A phase II double window of opportunity trial evaluating the oral TGF-beta receptor I inhibitor vactosertib in patients undergoing standard of care preoperative therapy for locally advanced esophageal adenocarcinoma.
TPS516 Background: Esophageal adenocarcinoma (EAC) is the seventh most common cancer globally and ranks sixth in overall mortality. Despite improvements i...
Impact of pancreatic tumour biomechanics on diagnosis and post-operative complications.
756 Background: Around 600 people are diagnosed with pancreatic cancer in Ireland each year, with 90% of these having pancreatic ductal adenocarcinoma (PD...
Circulating tumor DNA for predicting complete response to total neoadjuvant therapy in locally advanced rectal cancer: ENSEMBLE-2.
284 Background: Total neoadjuvant therapy (TNT) has dramatically shifted the paradigm in the treatment of locally advanced rectal cancer (LARC), prolongin...
Disparities in stage of diagnosis of colon cancer: Differences by Hispanic background, race, and ethnicity.
24 Background: Given noted heterogeneity in Hispanic adults, cancer outcomes reported in aggregate may not detect disparities within specific Hispanic sub...
HERIZON-BTC-302: A phase 3 study of zanidatamab with standard-of-care (SOC) therapy vs SOC alone for first-line treatment of human epidermal growth factor receptor 2 (HER2)-positive advanced/metastatic biliary tract cancer (BTC).
TPS648 Background: Zanidatamab is a humanized, IgG1-like, HER2-targeted bispecific antibody that simultaneously binds to 2 non-overlapping domains on HER2...
Impact of Lauren’s subtype in locally-advanced gastric cancer (LAGC) prognosis: A call for change.
497 Background: Patients with LAGC should undergo perioperative chemotherapy and surgery. Lauren’s diffuse subtype and signet-ring cell carcinoma have bee...
Intraperitoneal and intravenous paclitaxel plus S-1 versus intravenous paclitaxel plus S-1 in gastric cancer patients with peritoneal metastasis: Results from the multicenter, randomized, phase 3 DRAGON-01 trial.
327 Background: The optimal chemotherapeutic regimen for gastric cancer with peritoneal metastasis remains undefined. We e...
Racial disparities in cancer stage at diagnosis among older adults with gastrointestinal cancers in the southeastern United States.
806 Background: Prior studies have documented racial disparities in survival among older adults with various gastrointestinal (GI) cancers, but mechanisms...
Safety and efficacy of combining PD-L1 and CTLA-4 blockade with transarterial chemoembolization in intermediate-stage hepatocellular carcinoma: A phase II study.
609 Background: Transarterial chemoembolization (TACE) is the standard treatment for intermediate-stage hepatocellular car...
Comparison of mutational landscape in primary and metastatic pancreatic tumors.
781 Background: Genomic profiling has brought to the forefront the clinical relevance of intratumoral heterogeneity. Oncogenic KRAS...
Characterization of the tumor immune microenvironment (TIME) and somatic landscape in gastrointestinal (GI) malignancies with <i>MTAP</i> deletions (del).
835 Background: PRMT5 is a synthetic lethality target in patients (pts) with MTAP...
Real-world clinical outcomes of locally advanced unresectable and de-novo metastatic pancreatic ductal adenocarcinoma: A multicenter retrospective study from Saudi Arabia.
691 Background: Pancreatic ductal adenocarcinoma (PDAC) has dismal clinical outcomes, even with existing treatment regimens. This study evaluates the clin...
Effect of marital status and race on survival of patients with well differentiated neuroendocrine tumors (NETs).
654 Background: Socioeconomic status factors (SES) such as marital status, income, and race can influence and enhance disparities in cancer incidence and...
Personalized frailty risk assessment in long-term survivors of colorectal cancer.
65 Background: Frailty, a pathologic form of aging, is associated with reduced quality of life and increased risk of death. Its incidence increases with a...
Factors and timing of decreased adherence to S-1 in postoperative docetaxel + S-1 therapy for gastric cancer.
403 Background: The combination of docetaxel + S-1 (DS) therapy in postoperative adjuvant treatment for gastric cancer has proven to be effective and has...
Changes in peri-operative chemotherapy and radiation use among patients with resected pancreatic ductal adenocarcinoma (PDAC) between 2004-2021 in the US SEER dataset.
697 Background: PDAC peri-operative management changed over 20 years. Randomized data supports adjuvant and multiagent chemotherapy (CT), while peri-opera...
Impact of intrathecal targeted drug delivery (ITDD) on oral morphine equivalents and pain scores in advanced pancreatic cancer pain.
686 Background: Pancreatic cancer accounts for approximately 3% of all cancers and affects ~64,000 adults in the United States each year. Seventy five per...
Clinical relevance of tumor fraction assessment from circulating tumor DNA in metastatic colorectal cancer.
237 Background: Both tissue (TBx) and liquid (LBx) biopsies are indicated for detecting actionable alterations in metastat...